Universal Beteiligungs und Servicegesellschaft mbH Buys Shares of 106,896 ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)

Key Points

• Universal Beteiligungs und Servicegesellschaft mbH acquired 106,896 shares of ACADIA Pharmaceuticals, valued at approximately $1,776,000, reflecting a 0.06% ownership stake in the company.
• Several institutional investors, including Vanguard Group Inc. and Assenagon Asset Management, have increased their holdings in ACADIA Pharmaceuticals, which is now 96.71% owned by institutional investors and hedge funds.
• Analysts have a consensus rating of "Moderate Buy" for ACADIA Pharmaceuticals, with an average target price of $28.13, and various firms have upgraded their price targets recently.

Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD - Free Report) during the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund bought 106,896 shares of the biopharmaceutical company's stock, valued at approximately $1,776,000. Universal Beteiligungs und Servicegesellschaft mbH owned 0.06% of ACADIA Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in ACAD. Assenagon Asset Management S.A. purchased a new stake in ACADIA Pharmaceuticals during the 1st quarter worth about $60,845,000. Point72 Asset Management L.P. purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth about $40,935,000. Norges Bank purchased a new stake in ACADIA Pharmaceuticals during the 4th quarter worth about $25,555,000. Renaissance Technologies LLC increased its holdings in ACADIA Pharmaceuticals by 204.2% during the 4th quarter. Renaissance Technologies LLC now owns 1,226,533 shares of the biopharmaceutical company's stock worth $22,507,000 after purchasing an additional 823,333 shares during the period. Finally, Two Sigma Advisers LP increased its holdings in ACADIA Pharmaceuticals by 160.8% during the 4th quarter. Two Sigma Advisers LP now owns 1,263,200 shares of the biopharmaceutical company's stock worth $23,180,000 after purchasing an additional 778,900 shares during the period. Hedge funds and other institutional investors own 96.71% of the company's stock.

Insider Activity at ACADIA Pharmaceuticals

In other ACADIA Pharmaceuticals news, insider James Kihara sold 4,000 shares of the firm's stock in a transaction dated Friday, May 16th. The stock was sold at an average price of $22.50, for a total value of $90,000.00. Following the transaction, the insider directly owned 20,395 shares of the company's stock, valued at $458,887.50. This trade represents a 16.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director Laura Brege sold 14,446 shares of the firm's stock in a transaction dated Wednesday, June 4th. The shares were sold at an average price of $21.78, for a total value of $314,633.88. Following the completion of the transaction, the director directly owned 15,095 shares in the company, valued at $328,769.10. This trade represents a 48.90% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 20,446 shares of company stock worth $454,634. 28.30% of the stock is owned by insiders.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the company. UBS Group lowered their price objective on ACADIA Pharmaceuticals from $25.00 to $22.00 and set a "buy" rating for the company in a research report on Monday, April 28th. BMO Capital Markets upped their target price on ACADIA Pharmaceuticals from $24.00 to $28.00 and gave the company an "outperform" rating in a research report on Monday, May 19th. Royal Bank Of Canada upped their target price on ACADIA Pharmaceuticals from $26.00 to $38.00 and gave the company an "outperform" rating in a research report on Monday, June 23rd. Morgan Stanley set a $24.00 target price on ACADIA Pharmaceuticals and gave the company an "equal weight" rating in a research report on Tuesday, May 20th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $30.00 price objective on shares of ACADIA Pharmaceuticals in a research note on Thursday, June 26th. Six investment analysts have rated the stock with a hold rating, eleven have given a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, ACADIA Pharmaceuticals has an average rating of "Moderate Buy" and a consensus target price of $28.13.

ACADIA Pharmaceuticals Price Performance

NASDAQ:ACAD traded up $0.44 during trading hours on Monday, reaching $23.97. 565,139 shares of the company traded hands, compared to its average volume of 2,182,305. The firm's 50-day moving average is $22.18 and its 200-day moving average is $19.06. The stock has a market cap of $4.01 billion, a P/E ratio of 17.50, a P/E/G ratio of 6.54 and a beta of 0.70. ACADIA Pharmaceuticals Inc. has a 1-year low of $13.40 and a 1-year high of $25.23.

ACADIA Pharmaceuticals (NASDAQ:ACAD - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.01. ACADIA Pharmaceuticals had a return on equity of 17.46% and a net margin of 22.97%. The business had revenue of $244.32 million for the quarter, compared to analysts' expectations of $239.32 million. During the same quarter last year, the firm earned $0.10 earnings per share. The business's revenue was up 18.7% on a year-over-year basis. As a group, research analysts predict that ACADIA Pharmaceuticals Inc. will post 0.7 earnings per share for the current year.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.